Items tagged with Treatment
Daily therapy superior to intermittent for TB in patients with HIV (post)
A daily antituberculosis regimen prevented rifampicin resistance and was more effective than an intermittent regimen among patients with HIV with pulmonary tuberculosis who were receiving antiretroviral therapy, according to findings published in JAMA Internal Medicine.
Preventive TB therapy during pregnancy causes excessive adverse events (post)
BOSTON — Researchers reported that the immediate initiation of isoniazid preventive therapy for tuberculosis during pregnancy produced an unexpectedly high incidence rate of severe treatment-related adverse events among women with HIV. However, they said the rate was comparable to that among women who initiated therapy postpartum, suggesting that women should be given a choice of when to initiate therapy.
Shorter TB regimens associated with greater treatment adherence (post)
Shorter treatment regimens for tuberculosis (TB) were associated with increased completion rates and fewer adverse events compared with traditional regimens, according to a study published in Pediatrics.
Extreme TB: Centre yet to push for cheaper versions of two crucial drugs (post)
Advanced patented medicines used to treat Drug Resistant Tuberculosis (DR-TB) are available to only about 1,000 patients out of the tens of thousands who need it, because the innovator-manufacturers are not ready to licence Indian drug-makers who can sell them at affordable prices.
WHO launches plan for cheaper TB drugs (post)
The World Health Organisation (WHO), on Tuesday (March 6), invited pharmaceutical companies around the world to submit proposals to manufacture affordable versions of newer medicines for treatment of drug-resistant tuberculosis (DR-TB).
Indian government negotiating with firms for better access to new TB drugs (post)
The government wants Johnson & Johnson and Mylan to provide treatment for multidrug-resistant TB patients as part of the Revised National Tuberculosis Control Programme.
J&J, Macleods in talks for license deal of TB drug (post)
Mumbai-based Macleods Pharmaceuticals and US drug giant Johnson & Johnson (J&J) are in talks for a voluntary license deal for the TB drug bedaquiline.
Janssen Pharmaceutica to expand production of Sirturo in Russia (post)
Janssen Pharmaceutica, which is part of US healthcare giant Johnson & Johnson, plans to increase production of its Sirturo (bedaquiline) – an anti-tuberculosis drug – in Russia, at the capacities of a local drugmaker Pharmstandard, according to recent statements of the companies, reports The Pharma Letter’s local correspondent.
North and south cooperation to combat TB (post)
Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and the University of Zurich were able to demonstrate that the levels of medication used are often too low. As a result, patients remained contagious with the dangerous disease for longer than necessary.
Otsuka's DELTYBA approved in China for the treatment of multidrug-resistant TB (post)
Otsuka Pharmaceutical Co., Ltd. announces that on March 12, DELTYBA® Tablets 50 mg (generic name: delamanid) received regulatory approval by the China Food and Drug Administration. Approval was granted for the manufacture and marketing of DELTYBA as a treatment for multidrug-resistant, pulmonary tuberculosis (MDR-TB) in adults.
Page 38 of 108 · Total posts: 0
←First 37 38 39 Last→